399 related articles for article (PubMed ID: 26681918)
21. Nematode pyruvate dehydrogenase kinases: role of the C-terminus in binding to the dihydrolipoyl transacetylase core of the pyruvate dehydrogenase complex.
Chen W; Komuniecki PR; Komuniecki R
Biochem J; 1999 Apr; 339 ( Pt 1)(Pt 1):103-9. PubMed ID: 10085233
[TBL] [Abstract][Full Text] [Related]
22. Microenvironmental control of glucose metabolism in tumors by regulation of pyruvate dehydrogenase.
Golias T; Kery M; Radenkovic S; Papandreou I
Int J Cancer; 2019 Feb; 144(4):674-686. PubMed ID: 30121950
[TBL] [Abstract][Full Text] [Related]
23. Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma.
Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Harris AL;
Neoplasia; 2005 Jan; 7(1):1-6. PubMed ID: 15736311
[TBL] [Abstract][Full Text] [Related]
24. Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.
Zhang W; Su J; Xu H; Yu S; Liu Y; Zhang Y; Sun L; Yue Y; Zhou X
PLoS One; 2017; 12(6):e0179672. PubMed ID: 28617852
[TBL] [Abstract][Full Text] [Related]
25. Pyruvate Dehydrogenase Kinases in the Nervous System: Their Principal Functions in Neuronal-glial Metabolic Interaction and Neuro-metabolic Disorders.
Jha MK; Jeon S; Suk K
Curr Neuropharmacol; 2012 Dec; 10(4):393-403. PubMed ID: 23730261
[TBL] [Abstract][Full Text] [Related]
26. Pan-cancer analysis reveals PDK family as potential indicators related to prognosis and immune infiltration.
Tao S; Tao K; Cai X
Sci Rep; 2024 Mar; 14(1):5665. PubMed ID: 38453992
[TBL] [Abstract][Full Text] [Related]
27. Structure-based investigation of pyruvate dehydrogenase kinase-3 inhibitory potential of thymoquinone, targeting lung cancer therapy.
Alotaibi BS; Hakami MA; Anwar S; Mawkili W; Albaqami A; Hassan MI
Int J Biol Macromol; 2024 Apr; 265(Pt 2):131064. PubMed ID: 38518935
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylation of the pyruvate dehydrogenase complex precedes HIF-1-mediated effects and pyruvate dehydrogenase kinase 1 upregulation during the first hours of hypoxic treatment in hepatocellular carcinoma cells.
Zimmer AD; Walbrecq G; Kozar I; Behrmann I; Haan C
Hypoxia (Auckl); 2016; 4():135-145. PubMed ID: 27800515
[TBL] [Abstract][Full Text] [Related]
29. Reprogramming of aerobic glycolysis in non-transformed mouse liver with pyruvate dehydrogenase complex deficiency.
Patel MS; Mahmood S; Jung J; Rideout TC
Physiol Rep; 2021 Jan; 9(1):e14684. PubMed ID: 33400855
[TBL] [Abstract][Full Text] [Related]
30. Targeting the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis to discover potent PDK inhibitors through structure-based virtual screening and pharmacological evaluation.
Gan L; Yang Y; Liang Z; Zhang M; He Y; Zhang SL
Eur J Med Chem; 2024 Jan; 264():116008. PubMed ID: 38056298
[TBL] [Abstract][Full Text] [Related]
31. Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
Fang A; Luo H; Liu L; Fan H; Zhou Y; Yao Y; Zhang Y
Bioorg Med Chem Lett; 2017 Dec; 27(24):5450-5453. PubMed ID: 29150396
[TBL] [Abstract][Full Text] [Related]
32. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.
Mazurek S
Int J Biochem Cell Biol; 2011 Jul; 43(7):969-80. PubMed ID: 20156581
[TBL] [Abstract][Full Text] [Related]
33. Targeting glucose metabolism to develop anticancer treatments and therapeutic patents.
Zhou Y; Guo Y; Tam KY
Expert Opin Ther Pat; 2022 Apr; 32(4):441-453. PubMed ID: 35001793
[TBL] [Abstract][Full Text] [Related]
34. Histidine modifying agents abolish pyruvate dehydrogenase kinase activity.
Mooney BP; David NR; Thelen JJ; Miernyk JA; Randall DD
Biochem Biophys Res Commun; 2000 Jan; 267(2):500-3. PubMed ID: 10631090
[TBL] [Abstract][Full Text] [Related]
35. Loss of metabolic flexibility as a result of overexpression of pyruvate dehydrogenase kinases in muscle, liver and the immune system: Therapeutic targets in metabolic diseases.
Jeon JH; Thoudam T; Choi EJ; Kim MJ; Harris RA; Lee IK
J Diabetes Investig; 2021 Jan; 12(1):21-31. PubMed ID: 32628351
[TBL] [Abstract][Full Text] [Related]
36. Metabolic phenotype of bladder cancer.
Massari F; Ciccarese C; Santoni M; Iacovelli R; Mazzucchelli R; Piva F; Scarpelli M; Berardi R; Tortora G; Lopez-Beltran A; Cheng L; Montironi R
Cancer Treat Rev; 2016 Apr; 45():46-57. PubMed ID: 26975021
[TBL] [Abstract][Full Text] [Related]
37. VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells.
Moore JD; Staniszewska A; Shaw T; D'Alessandro J; Davis B; Surgenor A; Baker L; Matassova N; Murray J; Macias A; Brough P; Wood M; Mahon PC
Oncotarget; 2014 Dec; 5(24):12862-76. PubMed ID: 25404640
[TBL] [Abstract][Full Text] [Related]
38. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism.
Pathania D; Millard M; Neamati N
Adv Drug Deliv Rev; 2009 Nov; 61(14):1250-75. PubMed ID: 19716393
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia.
Sugden MC; Holness MJ
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Jul; 2(2):151-65. PubMed ID: 12476789
[TBL] [Abstract][Full Text] [Related]
40. Metabolic changes in cancer: beyond the Warburg effect.
Wu W; Zhao S
Acta Biochim Biophys Sin (Shanghai); 2013 Jan; 45(1):18-26. PubMed ID: 23257292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
